Skip to main content
SpringerLink
Log in

Bioresorbable Stents in PCI

  • New Therapies for Cardiovascular Disease (KW Mahaffey, Section Editor)
  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

The evolution of percutaneous coronary intervention has been considerable. Coronary stents were introduced to avoid vessel recoil and reduce acute and late vessel complications. Later, drug-eluting stents were developed to decrease the neointimal hyperplasia associated with bare metal stents in order to reduce restenosis. However, very late stent thrombosis remains problematic, and the permanent presence of a metal stent could be associated with local inflammation and impaired vascular physiology. Thus, bioresorbable stents have been developed, to prevent recoil initially when this risk is the highest, with subsequent degradation over time, to avoid long-term complications of the presence of stents in the coronary vasculature. Here, we review the current status of bioresorbable stents in percutaneous coronary intervention (PCI), with focus on the platforms that have been studied the most: ABSORB, DESolve, and DREAMS. In terms of clinical outcomes, bioresorbable stents have not yet shown superiority compared with current generation drug-eluting stents, but rather a signal of increased stent thrombosis. Further development and longer-term studies are needed before the routine implementation of bioresorbable stents in clinical practice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Grüntzig A. Transluminal dilatation of coronary-artery stenosis. Lancet. 1978;1(8058):263.

    Article  PubMed  Google Scholar 

  2. Yousuf O, Bhatt DL. The evolution of antiplatelet therapy in cardiovascular disease. Nat Rev Cardiol. 2011;8(10):547–59.

    Article  CAS  PubMed  Google Scholar 

  3. Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med. 1987;316(12):701–6.

    Article  CAS  PubMed  Google Scholar 

  4. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med. 1994;331(8):489–95.

    Article  CAS  PubMed  Google Scholar 

  5. Serruys PW, Unger F, Sousa JE, Jatene A, Bonnier HJ, Schönberger JP, et al. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med. 2001;344(15):1117–24.

    Article  CAS  PubMed  Google Scholar 

  6. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004;350(3):221–31.

    Article  CAS  PubMed  Google Scholar 

  7. Morice M-C, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346(23):1773–80.

    Article  CAS  PubMed  Google Scholar 

  8. Stettler C, Wandel S, Allemann S, Kastrati A, Morice M-C, Schömig A, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet. 2007;370(9591):937–48.

    Article  CAS  PubMed  Google Scholar 

  9. Lagerqvist B, James SK, Stenestrand U, Lindbäck J, Nilsson T, Wallentin L, et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med. 2007;356(10):1009–19.

    Article  CAS  PubMed  Google Scholar 

  10. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet. 2007;369(9562):667–78.

    Article  CAS  PubMed  Google Scholar 

  11. Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice M-C, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med. 2007;356(10):998–1008.

    Article  CAS  PubMed  Google Scholar 

  12. Bangalore S, Kumar S, Fusaro M, Amoroso N, Attubato MJ, Feit F, et al. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials. Circulation. 2012;125(23):2873–91. Lippincott Williams & Wilkins.

    Article  CAS  PubMed  Google Scholar 

  13. Sarno G, Lagerqvist B, Nilsson J, Fröbert O, Hambraeus K, Varenhorst C, et al. Stent thrombosis in new-generation drug-eluting stents in patients with STEMI undergoing primary PCI: a report from SCAAR. J Am Coll Cardiol. 2014;64(1):16–24.

    Article  PubMed  Google Scholar 

  14. Taniwaki M, Radu MD, Zaugg S, Amabile N, García-García HM, Yamaji K, et al. Mechanisms of very late drug-eluting stent thrombosis assessed by optical coherence tomography. Circulation. 2016;133(7):650–60. Lippincott Williams & Wilkins.

    Article  CAS  PubMed  Google Scholar 

  15. Cook S, Wenaweser P, Togni M, Billinger M, Morger C, Seiler C, et al. Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation. 2007;115(18):2426–34. Lippincott Williams & Wilkins.

    Article  CAS  PubMed  Google Scholar 

  16. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006;48(1):193–202.

    Article  PubMed  Google Scholar 

  17. Otsuka F, Vorpahl M, Nakano M, Foerst J, Newell JB, Sakakura K, et al. Pathology of second-generation everolimus-eluting stents versus first-generation sirolimus- and paclitaxel-eluting stents in humans. Circulation. 2014;129(2):211–23. Lippincott Williams & Wilkins.

    Article  CAS  PubMed  Google Scholar 

  18. Hofma SH, van der Giessen WJ, van Dalen BM, Lemos PA, McFadden EP, Sianos G, et al. Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. Eur Heart J. 2006;27(2):166–70. The Oxford University Press.

    Article  PubMed  Google Scholar 

  19. Hamilos M, Sarma J, Ostojic M, Cuisset T, Sarno G, Melikian N, et al. Interference of drug-eluting stents with endothelium-dependent coronary vasomotion: evidence for device-specific responses. Circ Cardiovasc Interv. 2008;1(3):193–200.

    Article  PubMed  Google Scholar 

  20. Marx SO, Totary-Jain H, Marks AR. Vascular smooth muscle cell proliferation in restenosis. Circ Cardiovasc Interv. 2011;4(1):104–11. Lippincott Williams & Wilkins.

    Article  CAS  PubMed  Google Scholar 

  21. Sarno G, Bruining N, Onuma Y, Garg S, Brugaletta S, De Winter S, et al. Morphological and functional evaluation of the bioresorption of the bioresorbable everolimus-eluting vascular scaffold using IVUS, echogenicity and vasomotion testing at two year follow-up: a patient level insight into the ABSORB A clinical trial. Int J Cardiovasc Imaging. 2012;28(1):51–8. Springer Netherlands.

    Article  PubMed  Google Scholar 

  22. Ormiston JA, Serruys PW, Regar E, Dudek D, Thuesen L, Webster MWI, et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet. 2008;371(9616):899–907.

    Article  CAS  PubMed  Google Scholar 

  23. Tanimoto S, Bruining N, van Domburg RT, Rotger D, Radeva P, Ligthart JM, et al. Late stent recoil of the bioabsorbable everolimus-eluting coronary stent and its relationship with plaque morphology. J Am Coll Cardiol. 2008;52(20):1616–20.

    Article  CAS  PubMed  Google Scholar 

  24. Serruys PW, Onuma Y, Ormiston JA, de Bruyne B, Regar E, Dudek D, et al. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes. Circulation. 2010;122(22):2301–12. Lippincott Williams & Wilkins.

    Article  CAS  PubMed  Google Scholar 

  25. Otsuka F, Pacheco E, Perkins LEL, Lane JP, Wang Q, Kamberi M, et al. Long-term safety of an everolimus-eluting bioresorbable vascular scaffold and the cobalt-chromium XIENCE V stent in a porcine coronary artery model. Circ Cardiovasc Interv. 2014;7(3):330–42. Lippincott Williams & Wilkins.

    Article  CAS  PubMed  Google Scholar 

  26. Serruys PW, Chevalier B, Dudek D, Cequier Á, Carrié D, Iñiguez A, et al. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet. 2015;385(9962):43–54.

    Article  CAS  PubMed  Google Scholar 

  27. Ellis SG, Kereiakes DJ, Metzger DC, Caputo RP, Rizik DG, Teirstein PS, et al. Everolimus-eluting bioresorbable scaffolds for coronary artery disease. N Engl J Med. 2015 Oct 12. This trial randomized 2008 patients to Absorb or DES and represents the largest trial comparing bioresorbable stents with DES.

  28. Gao R, Yang Y, Han Y, Huo Y, Chen J, Yu B, et al. Bioresorbable vascular scaffolds versus metallic stents in patients with coronary artery disease: ABSORB China trial. J Am Coll Cardiol. 2015;66(21):2298–309.

    Article  CAS  PubMed  Google Scholar 

  29. Kimura T, Kozuma K, Tanabe K, Nakamura S, Yamane M, Muramatsu T, et al. A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan. Eur Heart J. 2015;36(47):3332–42. The Oxford University Press.

    Article  PubMed  Google Scholar 

  30. Stone GW, Gao R, Kimura T, Kereiakes DJ, Ellis SG, Onuma Y, et al. 1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis. Lancet. 2016;387(10025):1277–89.

  31. Cassese S, Byrne RA, Ndrepepa G, Kufner S, Wiebe J, Repp J, et al. Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials. Lancet. 2015;387(10018):537–44.

  32. Puricel S, Arroyo D, Corpataux N, Baeriswyl G, Lehmann S, Kallinikou Z, et al. Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds. J Am Coll Cardiol. 2015;65(8):791–801.

    Article  CAS  PubMed  Google Scholar 

  33. Sabaté M, Windecker S, Iñiguez A, Okkels-Jensen L, Cequier A, Brugaletta S, et al. Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction-TROFI II trial. Eur Heart J. 2016;37(3):229–40. The Oxford University Press.

    Article  PubMed  Google Scholar 

  34. Lipinski MJ, Escarcega RO, Baker NC, Benn HA, Gaglia MA, Torguson R, et al. Scaffold thrombosis after percutaneous coronary intervention with ABSORB bioresorbable vascular scaffold: a systematic review and meta-analysis. JACC Cardiovasc Interv. 2016;9(1):12–24. This is the to date largest meta-analysis comparing bioresorbable stents with DES.

    Article  PubMed  Google Scholar 

  35. Verheye S, Ormiston JA, Stewart J, Webster M, Sanidas E, Costa R, et al. A next-generation bioresorbable coronary scaffold system: from bench to first clinical evaluation: 6- and 12-month clinical and multimodality imaging results. JACC Cardiovasc Interv. 2014;7(1):89–99.

    Article  PubMed  Google Scholar 

  36. Waksman R, Erbel R, Di Mario C, Bartunek J, de Bruyne B, Eberli FR, et al. Early- and long-term intravascular ultrasound and angiographic findings after bioabsorbable magnesium stent implantation in human coronary arteries. JACC Cardiovasc Interv. 2009;2(4):312–20.

    Article  PubMed  Google Scholar 

  37. Ghimire G, Spiro J, Kharbanda R, Roughton M, Barlis P, Mason M, et al. Initial evidence for the return of coronary vasoreactivity following the absorption of bioabsorbable magnesium alloy coronary stents. EuroIntervention. 2009;4(4):481–4.

    Article  PubMed  Google Scholar 

  38. Haude M, Erbel R, Erne P, Verheye S, Degen H, Böse D, et al. Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man BIOSOLVE-I trial. Lancet. 2013;381(9869):836–44.

    Article  CAS  PubMed  Google Scholar 

  39. Haude M, Ince H, Abizaid A, Toelg R, Lemos PA, von Birgelen C, et al. Safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de-novo coronary artery lesions (BIOSOLVE-II): 6 month results of a prospective, multicentre, non-randomised, first-in-man trial. Lancet. 2016;387(10013):31–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden

    Daniel Lindholm & Stefan James

  2. Uppsala Clinical Research Center, Dag Hammarskjölds väg 14B, SE-752 37, Uppsala, Sweden

    Daniel Lindholm & Stefan James

Authors
  1. Daniel Lindholm
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stefan James
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniel Lindholm.

Ethics declarations

Conflict of Interest

Daniel Lindholm reports institutional grants and lecture fees from AstraZeneca.

Stefan James reports institutional grants for trials from Abbot Vascular.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on New Therapies for Cardiovascular Disease

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lindholm, D., James, S. Bioresorbable Stents in PCI. Curr Cardiol Rep 18, 74 (2016). https://doi.org/10.1007/s11886-016-0750-9

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11886-016-0750-9

Keywords

Search

Navigation